$188.20 Million in Sales Expected for Emergent Biosolutions Inc (EBS) This Quarter
Wall Street brokerages expect Emergent Biosolutions Inc (NYSE:EBS) to announce sales of $188.20 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Emergent Biosolutions’ earnings, with the highest sales estimate coming in at $191.40 million and the lowest estimate coming in at $185.00 million. Emergent Biosolutions reported sales of $149.43 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 25.9%. The firm is expected to report its next earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Emergent Biosolutions will report full-year sales of $746.54 million for the current fiscal year, with estimates ranging from $743.50 million to $751.90 million. For the next fiscal year, analysts forecast that the firm will report sales of $826.06 million per share, with estimates ranging from $756.30 million to $931.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Emergent Biosolutions.
Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.19. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The company had revenue of $220.20 million for the quarter, compared to analysts’ expectations of $208.94 million. During the same period last year, the business earned $0.13 EPS. Emergent Biosolutions’s quarterly revenue was up 118.5% compared to the same quarter last year.
In other news, Chairman Fuad El-Hibri sold 15,000 shares of the firm’s stock in a transaction on Monday, July 9th. The stock was sold at an average price of $53.61, for a total transaction of $804,150.00. Following the completion of the sale, the chairman now directly owns 1,539,993 shares of the company’s stock, valued at approximately $82,559,024.73. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Daniel Abdun-Nabi sold 15,785 shares of the firm’s stock in a transaction on Tuesday, June 5th. The shares were sold at an average price of $52.11, for a total value of $822,556.35. Following the sale, the chief executive officer now directly owns 197,343 shares of the company’s stock, valued at $10,283,543.73. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 88,856 shares of company stock worth $4,832,028. Company insiders own 13.40% of the company’s stock.
Several institutional investors have recently made changes to their positions in EBS. Stratos Wealth Partners LTD. purchased a new stake in shares of Emergent Biosolutions during the 1st quarter valued at $134,000. PNC Financial Services Group Inc. increased its position in shares of Emergent Biosolutions by 108.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 1,482 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Emergent Biosolutions during the 1st quarter valued at $171,000. Financial Gravity Wealth Inc. purchased a new stake in shares of Emergent Biosolutions during the 1st quarter valued at $190,000. Finally, Sei Investments Co. increased its position in shares of Emergent Biosolutions by 5,992.1% during the 1st quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 3,775 shares during the last quarter. 82.72% of the stock is owned by hedge funds and other institutional investors.
NYSE:EBS traded up $0.24 during trading hours on Tuesday, hitting $59.27. 238,117 shares of the company traded hands, compared to its average volume of 331,743. The company has a current ratio of 5.59, a quick ratio of 4.15 and a debt-to-equity ratio of 0.01. Emergent Biosolutions has a one year low of $34.56 and a one year high of $60.00. The stock has a market cap of $2.75 billion, a PE ratio of 31.19, a price-to-earnings-growth ratio of 1.18 and a beta of 1.20.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Further Reading: Understanding Stock Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.